Sequential administration of immunotherapy and targeted therapy prolongs anti-tumor responses news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
E-Mail
TAMPA, Fla. - Advanced melanoma is one of the deadliest types of cancer, with a 5-year survival rate of only 27% for patients with distant metastases. Recent advances in targeted therapies and immunotherapies have greatly improved patient prognosis; however, many patients eventually develop resistance and disease recurrence. Researchers at Moffitt Cancer Center are investigating how to combine and sequence new therapies to improve survival. In a new article published in
Cancer Immunology Research, the Moffitt team shows that sequential administration of immunotherapy followed by targeted therapy prolongs anti-tumor responses in preclinical models and may be a potential treatment option for patients.